Europe
United Kingdom
Europe
United Kingdom

The 'go to' European specialist pharma company

Targaxan® 550mg

TargaxanRifaximin-α

 

 

TARGAXAN is licensed in the UK for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age (see section 5.1).


In the pivotal study, 91% of the patients were using concomitant lactulose.


Consideration should be given to official guidance on the appropriate use of antibacterial agents.

 

The links below will redirect you to an alternative site not maintained by Norgine Pharmaceuticals Limited

 

View the Patient Information Leaflet                           

View the Summary of Product Characterisitics

 

 

Please consult with your Doctor, or other qualified Healthcare Professional before use.

 

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

 

By reporting side effects you can help provide more information on the safety of this medicine.

 

UK/COR/0814/0097b

Last update: January 2016